Skip to content

Guided Poster Tour

Here you can find all the abstracts, presented at the Guided Poster Tour taking place on Wednesday, 19.11.2025 from 19h00 - 20h30, Hall 4.0 (close to the session rooms)

Guided Poster Tour Station 1 - Hemostasis, transfusion medicine, vascular, laboratory medicine, benign hematology

Chairs: Vera Ulrike Bacher (Inselspital), Jeremy Deuel (UniversitätsSpital Zürich)

  1. Long-term outcomes in patients with antiphospholipid antibody monopositivity and initial venous thrombosis: a retrospective cohort study - M. I. iarossi, A. C. Casini, P. F. Fontana
  2. Correlation between the level of hemoglobin variants (HbS, C and E) and alpha-thalassaemia - M. Da Costa Rogao, C. Noppen, G. Colucci, C. Kalberer
  3. Use of Pegcetacoplan in Swiss Patients with Paroxysmal Nocturnal Hemoglobinuria – Retrospective Case Series Analysis - E. H. Häfliger, A. R. Rovó, B. D. Drexler, A. H. Holbro, M. B. Bissig, G. S. Stüssi, N. F. Fiorelli, P. L. Lovey
  4. BlastenBlaster – An interactive learning program for blood and bone marrow cell differentiation - O. Hoffmann, S. Balabanov, J. W. Deuel
  5. Defining indications for thrombophilia testing– a modified Delphi consensus study in Switzerland - A. Bosch, C. Suter, L. Graf, S. Ruosch-Girsberger
  6. Clinical utility of thrombin generation using ST-Genesia® instrument in patients with hereditary and acquired thrombophilia - L. Caspary, J. Shaw, O. Stalder, J. Brodard, A. Angelillo-Scherrer, K. Vrotniakaite-Bajerciene
  7. What is the best way for a blood bank to manage immune-hematological interference related to Daratumumab treatment? - P. Stakia, S. Waldvogel-Abramowski
  8. Biopsy-based KIT D816V digital droplet PCR improves detection of residual disease after allogeneic hematopoietic cell transplantation in systemic mastocytosis - A. Stelmes, J. R. Passweg, J. P. Halter, F. Matteazzi, A. Tzankov, S. Dirnhofer, T. Menter, I. Bratic Hench, V. Perrina, M. S. Bader
  9. Mitochondrial DNA Enhances Adrenaline-Induced Platelet Activation in Type-II Diabetes Mellitus - D. Shehwar, A. Aliotta, M. Rasool, S. Fatima, S. Barki, D. B. Calderara, L. Veuthey, C. P. Portela, K. Haeri, M. R. Alam, L. Alberio
  10. Evaluation of Sebia Free Light Chain ELISA Tests in a routine diagnostic laboratory - M. Dervisi, R. Schoumacker, D. Venet, C. Kalberer, G. Colucci
  11. Case report: a novel approach to prevent chronic histiocytic intervillositis and recurrent pregnancy loss by targeting maternal alloimmunity - M. Gavillet, C. Gengler, H. Legardeur, M. Gannagé, J. Puder, L. Beauport, A. Panchaud Monnat, S. Rotman, D. Comte, D. Baud, D. Golshayan
  12. Impact of recalcification on procoagulant COAT platelet generation in PRP samples with low platelet counts - L. Hayenga, L. Veuthey, M. Krüsi, K. Haeri, D. Bertaggia Calderara, L. Alberio, A. Aliotta
  13. Spontaneous post-orthopedic HIT-like syndrome: a case report and literature review with diagnostic / therapeutic recommendations for a rare life-threatening complication - M. G. Zermatten, N. Friedrich, F. Grandoni, M. Gavillet, A. Aliotta, F. J. Gomez, L. Alberio

Poster only (without presentation)

  1. Achieving remission with the second generation BTK-inhibitor zanubrutinib in a male patient with steroid-refractory recurrence of immune-mediated thrombotic thrombocytopenic purpura - A. D. De Angelis, I. Chanias, A. S. Schnegg-Kaufmann, J. A. Kremer Hovinga Strebel
  2. HbF-inducing gene therapies for β-hemoglobinopathies: materno-fetal implications in future pregnancies and a framework for antenatal surveillance - M. Gavillet, H. Legardeur, C. Adam, R. Renella, P. Dashraath, D. Baud
  3. Platelets phagocytosis in acute Dengue infection - N. Michel, B. Favre, S. M. D'Almeida, G. Colucci
  4. Compound HFE/PIGA Mutation as cause of hemochromatosis and neurological dysfunction: case report of a Swiss patient - C. Medri, A. Jauch, L. Infanti
  5. The comparison between bone marrow smear using the cover slip technique and the slide technique in bone marrow procedure, the clinical laboratory of department of medicine, faculty of medicine, Khon Kaen University - K. Chootawiriyasakul, N. Teawtrakul, P. Klungsaeng
  6. Utility of screening for aberrant T-cell marker expression in diagnostic evaluation of plasmablastic myeloma: A case report. - J. Tossounidis, C. Segalada, J. Dirks
  7. Operational performance evaluation of two Tests for Free Light Chain in Serum - M. Dervisi, R. Schoumacker, N. Zennaf, C. Kalberer, G. Colucci
  8. JAK2V617F mutation in northeast Thailand patients with Myeloproliferative neoplasms. - K. Chootawiriyasakul, N. Teawtrakul, C. Wanitpongpun, S. Sanmai

Guided Poster Tour Station 2 - Clinical hemato-oncology

Chairs: Chiara Bernardi (HUG), Astrid Tschan-Plessl (University Hospital Basel)

  1. Association of CAR T-Cell Area Under the Curve with Clinical Outcomes in Patients Treated with Tisagenlecleucel: A Real-World Study - D. M. Devin Meier, G. W. Gertrud Wiedemann, J. R. Jean-Benoît Rossel, U. B. Vera Ulrike Bacher, T. P. Thomas Pabst, A. S. Anne Angelillo-Scherrer, I. C. Ioannis Chanias, M. D. Michael Daskalakis, K. J. Katarzyna Aleksandra Jalowiec
  2. Causes of death in 5- and 10-year survivors after allogeneic hematopoietic cell transplantation. - M. Aicher, R. Mathew, B. Drexler, A. Stelmes, J. van den Berg, F. Matteazzi, D. Heim, B. Steegmüller, H. Baldomero, J. R. Passweg, J. P. Halter
  3. Comprehensive Screening & Monitoring for systemic Light Chain Amyloidosis in Patients with Monoclonal Gammopathy of clinical significance (COSMO-AL) - M. Rieger, R. Schwotzer
  4. The Glasgow Prognostic Score adds Prognostic Information in Elderly AML Patients Ineligible for Intensive Treatment Independently from the Molecular Risk Profile – a Retrospective Multicentre Analysis - S. Fuchs, V. Petermichl, M. Weber, C. Micheloud, L. Graf, Y. Gerth, J. S. Goede, T. Lehmann, C. Driessen, U. Mey, R. Cathomas, S. Cogliatti, T. Silzle
  5. Impact of body mass index (BMI) on response and tolerance to azacitidine (AZA) in myeloid neoplasms (MN) - C. Barfuss, G. Tsilimidos, S. Blum
  6. Outcome, quality of life and patient expectations of the first 55 CAR-T patients at our hospital - T. Lehmann, G.-A. Lehmann, M. Fehr, M. Volden, C. Driessen, J. Thierbach
  7. Therapy refractory ICANS after CAR T cell therapy with Brexucabtagene-Autoleucel (Tecartus) for Relapsed Mantle Cell Lymphoma: Successful Management with Intrathecal Triple Chemotherapy - M. Meier, K. Baur, T. Weber, N. Völkle, C. Anderegg, S. Gerull
  8. Pseudo-Richter Transformation in a patient with chronic lymphatic leukemia after cessation of therapy with Venetoclax/Ibrutinib - R. B. Battegay, D. H. Heim, S. D. Dirnhofer
  9. Systemic AL-amyloidosis diagnosed via histopathological screening in patients undergoing carpal tunnel surgery: A case report. - C. M. Hagen, S. Schelb, M. Bertschinger, G. Broccoli, O. Wigger, A. Furrer, J. S. Goede
  10. Elranatamab for relapsed/refractory multiple myeloma with severe renal impairment requiring hemodialysis - M. Hoffmann, B. Jeker, U. Huynh-Do, Y. Banz, J. Godau, E. Weber, U. Bacher, T. Pabst
  11. Follicular T-Helper cell lymphoma of the Angioimmunoblastic type with associated Marginal zone lymphoma – a diagnostic and therapeutic challenge - B. Okamura, J. Dirks, D. Ditz, C. Winterhalder, A. Tzankov, S. Dirnhofer, E. Heilmann, C. C. Widmer

Guided Poster Tour Station 3.1 - Experimental hematology / oncology

Chair: Petya Apostolova (Universitätsspital Basel)

  1. Dissecting MLL–ENL and MLL–ELL Fusions in Infant AML: a CRISPR Human HSPC Model for Biology and Therapy - A. Menchaca Muñiz, P. Radszuweit, A. Parshenkov, M. Manz, D. Schneidawind, C. Schneidawind
  2. Machine learning approach identifies targeting strategy for selective AML dependency - E. Provenzano, M. Burocziova, A. Baumann, P. Suominen, T. R. Eeksman, E. Krainer, J. M. Ellegast
  3. PD-L1: a novel therapeutic target in mastocytosis - E. Ratti, S. Stivala, E. Sheremeti, L. Clauss, A. Makeeva, T. Almeida, M. Usart, M. Konantz, K. Hartmann
  4. Modeling Advanced Systemic Mastocytosis: An Inducible Kit D814V Mouse as a Preclinical In Vivo Platform for Therapeutic Development - M. Konantz, L. Clauss, A. Makeeva, E. Ratti, E. Sheremeti, T. Almeida Turpin, M. Usart, S. Stivala, K. Hartmann
  5. B-cell receptor repertoire profiling reveals distinct clonal architectures and early lymphoma-associated patterns in PPBL - B. Besemer, P. Schmidt-Barbo, K. Pini, F. Poletti, R. Hupfer, A. Stiefvater, C. Schultheiss, M. Recher, M. Binder
  6. Unraveling apoptosis and autophagy mediated mechanisms contributing to the pathogenesis of pediatric Immune Thrombocytopenia - C. Bitsina, M. Seiler, M. Schmugge, F. D. Franzoso
  7. TGFβ driven metabolic reprogramming of PDL1+ macrophages defines a targetable axis of immune evasion in diffuse large B cell lymphoma - N. Cui, A. Müller
  8. Inflammation-mediated Resistance to FLT3 Inhibition in Acute Myeloid Leukemia - P. Suominen, K. Rajeeth, P. Gueguen, M. Burocziova, J. Deuel, S. Balabanov, M. G. Manz, X. Chen, C. Nombela-Arrieta, J. M. Ellegast

Guided Poster Tour Station 3.2 - Experimental hematology / oncology

Chair: Thibaud Kössler (Hôpitaux Universitaires de Genève)

  1. CAR T Cells Secreting Synthetic Proteins to Target Solid Tumors - L. Hörtensteiner, M. Wehrli
  2. Overall survival in patients with Recurrent/Metastatic Head and Neck cancer after systemic therapy treated with an encapsulation-based cellular immunotherapy - E. Fernandez, R. Vernet, M. Urwyler, O. Von Rohr, E. Charrier, M. C. Belkouch, V. Saingier, F. Courtout, C. De Vito, V. Ancrenaz, N. Dulguerov, W. Karenovics, J. Grogg, J. Renaux, G. Muller, K. Gobat, T. Brezina, T. Rordorf, M. Joerger, O. Michielin, J. Villard, N. Mach
  3. Oncogenic splicing of the p53-related tumorsuppressor ASPP2 drives tumor aggressiveness and therapy resistance in pancreatic cancer - K. M. Kampa-Schittenhelm, W. Liu, M. M. Schittenhelm, C. Driessen
  4. Cytokine-induced hexokinase 3 (HK3) supports macrophage cell survival - C. G. Kalbermatter, Y. H. Mady, A. M. Schläfli, T. Kaufmann, B. E. Torbett, M. P. Tschan
  5. Identifying Novel Vulnerabilities in Clear Cell Sarcoma Through Functional and Genomic Screening - L. P. Leuenberger, L. Isenegger, Y. Chen, M. Burri, S. Kollar, L. Planas-Paz, P. K. Bode, A. Wozniak, S. Bauer, P. Schöffski, C. Pauli, C. Britschgi
  6. Targeting the thyroid-stimulating hormone receptor in poorly-differentiated thyroid cancer with CD3-engaging bispecific antibodies or CAR T cells - C. Fischer, A. Eugster, C. Schultheiß, E. D`Arcangelo, F. Filipsky, S. Stücheli, C. Wickenhauser, M. Bauer, K. Lorenz, J. Jakscha, L. Müller, R. Köberle-Wührer, B. Kasenda, C. Rottenburger, R. Latif, T. F. Davies, H. Läubli, M. Peipp, M. Binder
  7. Targeting Long-Chain Fatty Acid Elongation Disrupts Cancer Membranes Organization and Triggers Anti-Cancer Immunity - J. Epiney, A. Santamaria-Martínez, A. Kasapoglu, N. Katanayeva, P. A. Miranda Herrera, J. A. Maillat, L. Abrami, E. Dheilly, G. Dienes, M. Bruand, S. Ho, L. Wedemann, M. Pavlou, R. Hamelin, F. Armand, G. Turcatti, F. Kuttler, M. Chambon, P. Fournier, F. Bretegnol, T. Hannich, V. Zoete, G. Ciriello, M. Schuhmacher, G. van der Goot, G. D’Angelo, E. Oricchio
  8. Regulation of cancer cell metabolism and proteostasis by mechanical tissue cues - J. Hill, M. Román-Trufero, K. Blighe, E. Gentleman, H. Auner

Poster only (without presentation), Station 3.1

  1. The BTK-degrader BGB-16673 and the BCL2-inhibitor sonrotoclax are active as single agents and in combination in marginal zone lymphoma models - A. J. Arribas, E. Civanelli, C. Scalise, L. Cascione, A. Rinaldi, D. Rossi, E. Zucca, F. Bertoni
  2. Locus specific proteomics identify potential regulators of the MYC super enhancer in NOTCH-driven T-ALL - J. Zaric, D. Chiappe, A. Guerrade Souza, F. Armand, M. Pavlou, N. Fournier, O. Naveiras, F. Radtke
  3. Analysis of Published Case Reports on Lymphoma Using Large Language Models - F. D. Dennstädt, N. B. Bonadies, A. H. Handra, N. C. Cihoric
  4. Transcriptional regulation of cell fate plasticity in hematopoiesis - A. Kamal, J. Zaugg, E. Vlachou
  5. Evaluation of translational potential of research focused on hematological neoplastic diseases – results of a large-scale analysis of PubMed and iCite databases - N. Cihoric, N. Bonadies, F. Dennstädt
  6. Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer - PARTACER-Suisse (SAKK 41-23, Trial in Progress) - H. Stricker, C. P. Clelia Pistoni, L. Cifric, S. Hussung, E. Keller, K. Eckhardt, Z. Balázs, M. Krauthammer, M. Scharl, T. Brummer, A. Wicki, M. Novak, M. Zoche, A. Weber, R. Fritsch
  7. Synergistic Effects of Immunotherapy and Chemotherapy in Reducing Drug Resistance in Leukemia Cells - H. Erfanian

Guided Poster Tour Station 4 - Clinical solid tumor oncology

Chairs: Kathrin Vollmer (Spital STS AG Thun), Eugenio Fernandez (Hôpitaux universitaires de Genève)

  1. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study - J. Huober, S. M. Tolaney, E. de Azambuja, K. Kalinsky, S. Loi, S.-B. Kim, C. Yam, B. Rapoport, S.-A. Im, B. Pistilli, W. McHayleh, D. W. Cescon, J. Watanabe, A. L. Banuelas, R. Freitas-Junior, J. Salvador Bofill, M. Afshari, D. Gary, L. Wang, C. Lai, P. Schmid
  2. Adjuvant Therapy in Early Breast Cancer: Meta-Analysis - N. Samai
  3. Methylthioadenosine Phosphorylase (MTAP)-loss and KRAS Mutations in patients with advanced non-small cell lung cancer (NSCLC) - O. Chijioke, F. Locher, S. Savic Prince, L. Roma, L. Bubendorf, D. König, B. Kasenda
  4. Single-Cell Co-Expression Networks reveal Actionable Resistance Mechanisms to Targeted and Immunotherapy treatments in Melanoma. - E. Camarillo-Retamosa, L. Bosshard, L. Klein, P. Rahimzadeh, B. Gosztonyi, Z. Balázs, N. Miglino, F. Singer, T. Tumor Profiler Consortium, M. Prummer, A. Wicki
  5. Impact of Platinum Dosing Intensity in Patients with Advanced Lung Cancer Treated with Palliative Chemotherapy or Chemo-Immunotherapy - S. Wehren, M. Galvanone, C. Bollinger, M. Vetter, T. Wallrabenstein
  6. Gender-specific effects of tumour infiltrating clonal haematopoiesis in NSCLC. - D. Balsiger, M. Zoche, A. Wicki, J. W. Deuel
  7. IKF/AIO-PHERFLOT: Perioperative Chemoimmunotherapy with Translational Biomarker Analyses in Localized HER2-Positive Esophagogastric Adenocarcinoma - B. Thiele, C. Schultheiss, P. Schmidt-Barbo, M. Matter, A. Stein, J. Tintelnot, S.-E. Al-Batran, C. Pauligk, M. Binder
  8. Patient Characteristics and Treatment Patterns in Patients with Head and Neck Squamous Cell Carcinoma Undergoing Chemoradiotherapy - A. Brandt, C. Maerten, L. Muller, F. Thieringer, M. Radovic, M. Binder, B. Kasenda
  9. Molecular subtypes and their correlation with clinical outcomes in a real-world study of patients with extensive stage small cell lung cancer (ES-SCLC) undergoing combined chemo-immunotherapy - N. Zellweger, S. Schmid, M. Früh, M. Bertschinger, C. Wailbel, T. Losmanova, F. Cerciello, P. Froesch, M. Mark, A. Bettini, P. Haeuptle, V. Blum, S. Hayoz, K. Gobar, L. A. Mauti, S. Savic Prince, I. Alborelli, S. I. Rothschild
  10. Survival in Prostate Cancer with Novel Therapies: A Meta-Analysis - N. Samai
  11. Implementation of liquid biopsies in routine clinical care in patients with advanced solid cancer (LIQPLAT) - a single arm trial enabling randomized comparisons - A. M. Schmitt, J. M. Schwenke, P. Janiaud, H. Läubli, M. Binder, I. Alborelli, M. Matter, O. Chijioke, T. Vlajnic, C. Widmer, M. Briel, L. G. Hemkens, B. Kasenda
  12. The SAKK OvCaR Registry: First Interim Analysis of a Multicenter Swiss Ovarian Cancer Registry (OvCaR) - I. Colombo, M. Heubner, S. Schar, S. Wyss, V. Heinzelmann-Schwarz, U. Hasler-Strub, F. Siegenthaler, I. Labidi-Galy, E. Ciliberti, M. Nerone, V. Blum, M. Fehr, R. Zanetti Dällenbach, C. Uhlmann Nussbaum, G. Meili, C. Nay Fellay, C. Brams, H. Passmann-Kegel, C. Sessa, M. Vetter

Poster only (without presentation)

  1. Neoadjuvant Immunotherapy in Stage III Colon Cancer with Deficient Mismatch Repair: A Single-centre Experience - I. Zúñiga Ott, P. Georgios, I. Fuchs, H. Schreiber, B. Becker, S. Böhm, G. Ortega Sanchez
  2. Analysis of the clinical and tumor biological differences of pre- vs. postmenopausal ER-positive breast cancer based on 2029 patient cases - H. G. Hass, B. Muco, M. Seywald, V. Kunzmann, A. Wöckel
  3. Rare Lung Cancer with a Non-Functional NTRK Fusion: “A Cautionary Tale” - M. Haberecker, M. Schmid, U. Richter, I. Opitz, C. Schnoz, C. Pauli
  4. Clinical Benefit of PIK3CA Inhibition in Therapy-Refractory Endometrial Cancer: A Single-Case Report - T. Kahl, E. Leutgeb, J. Huober
  5. Unlikely five-year survival after R1 resection and metachronous oligometastasis in pancreatic ductal adenocarcinoma - B. Calle Serrano, G. Ortega Sánchez

Guided Poster Tour Station 5 - Nursing, supportive & palliative care, rehabilitation & survivorship and integrative oncology

Chairs: Claudia Gamondi (CHUV), Julia Reusch (Stadtspital Zürich Triemli), Carla Pedrazzani (SUPSI), Nadja Wyrsch (Rehabilitation Klinik Gais -Kliniken Valens)

  1. Cancer Survivorship Fatigue: Characteristics, Multimodal Fatigue Interventions (MMFI) and Time Course of 108 Cancer Fatigue Clinic (CFC) patients - E. Kara, F. Strasser
  2. Towards the Integration of Complementary Approaches within Oncology and Palliative Care Services: A Mixed-Methods Study at Geneva University Hospitals - J. Besson, A. Stettler, M. Gaignard, M. Ljuslin
  3. Dermatological reactions during antitumor therapies: Introduction of a skin assessment - V. Bickel, A. Lenz, K. Wernli, P. Bützberger
  4. A Delphi Consensus in Integrative Oncology: Towards Shared Principles and Criteria for Integration - N. Kalbermatten, S. Kohler, T. Corbière, P.-Y. Rodondi, A. Templeton, C. Witt, U. Wolf, M. Schlaeppi